Business
NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results
Company to Host Conference Call and Webcast March 31, 2022, at 8:30am ET RADNOR, Pa., March 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Company to Host Conference Call and Webcast March 31, 2022, at 8:30am ET\nRADNOR, Pa., March 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\"), a clinical-stage, biopharmaceutical company, today announced its financial results for the year ended December 31, 2021 and provided a business update.\n\n \n \n \n \n \n \n\n \nNRx Q4 Earnings Highlight New Leadership Team, Core-Business Focus on U.S., Zyesami and NRX 101\"NRx Pharmaceuticals was founded to address high unmet or life-threatening medical needs by applying innovative science to known molecules.\" said Robert Besthof, Interim Chief Executive Officer. \"We are excited to continue to build upon the foundation laid by our founder and my predecessor Dr. Jonathan Javitt. Today NRx is positioned to bring hope to life by executing our strategy in two priority areas in which we have Phase III compounds with Fast Track and Breakthrough Therapy designation, respectively: the development and approval of ZYESAMI® (aviptadil), for treatment of Critical COVID-19 and other respiratory diseases, and advancing our psychiatric portfolio, including NRX-101. Given a changing global geopolitical environment we believe it is prudent to narrow our geographic focus principally in the United States and where we can make the biggest contribution towards improving patient care in the near term. We look forward to advancing the late-stage studies of our promising pipeline of Phase III candidates in Psychiatry and Respiratory Diseases and realizing their potential for patients and investors.\"\nRecent Business Highlights Announced leadership transition - Robert Besthof named Interim CEO; Dr. Jonathan Javitt to serve as Chief Scientist, member of the Board of DirectorsCompany now geographically focused primarily in the U.S. on its two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidalityRe-initiating psychiatry development - initiating a Phase II study of NRX-101 for bipolar depression with sub-acute suicidal ideation and behavior (SSIB); plans to initiate a new Phase IIb/III registrational study of NRX-101 for severe bipolar depression with acute suicidal ideation and behavior (ASIB) using commercial level material in the se...